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ABSTRACT
Introduction: Patients with multiple sclerosis
(MS) generally undergo long-term treatment
with disease-modifying therapies (DMTs). In
the US, patients taking glatiramer acetate,
interferon beta-1a, or interferon beta-1b,
typically use a mechanical autoinjector. Recent
survey results have shown that using an
electronic autoinjector, such as
BETACONNECTTM (Bayer Pharma AG) for
interferon beta-1b/Betaseron (Bayer Pharma
AG) may reduce injection discomfort and
increase patient satisfaction with treatment.
The aim of the current survey was to assess
patient perceptions of BETACONNECT
compared with mechanical autoinjectors using
a survey integrated with demonstrations and
simulated injections with BETACONNECT.
Methods: Patients with MS currently using
mechanical autoinjectors for glatiramer
acetate/Copaxone (Teva Pharmaceuticals
USA, Inc.), interferon beta-1a/Rebif (EMD
Serono Inc.), or interferon beta-1b/Extavia
(Novartis Pharmaceuticals Corp.), participated
in a 60-min in-person interview. Patients rated
the importance of 18 ideal autoinjector
attributes, and the performance of their
current autoinjectors across these attributes.
BETACONNECT was demonstrated and
patients performed simulated injections with
BETACONNECT before rating it across the same
attributes. Patient overall autoinjector
preference was assessed.
Results: Ninety patients completed the survey:
63 were using autoinjectors for Copaxone, 25
for Rebif, and 2 for Extavia. BETACONNECT
scored higher than mechanical autoinjectors
across all 18 attributes. The top attributes of an
ideal autoinjector were the injection process is
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easy overall, easy to push the button to start the
injection, and autoinjector is comfortable to
hold during injections. Unique BETACONNECT
features most valued by patients were the
built-in dwell time, self-check function, greater
ability to customize injections, adjustment of
injection speed, low injection noise, and
automatic needle retraction. Overall, 75 out of
90 patients (83%) expressed a preference for
BETACONNECT over their current autoinjector.
Conclusion: BETACONNECT attributes and
features were highly rated by patients,
compared with both an ideal autoinjector and
their current mechanical autoinjectors. These
findings suggest that the use of BETACONNECT
may increase patient satisfaction and
potentially increase overall medication
adherence.
Funding: Bayer HealthCare Pharmaceuticals.
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Multiple sclerosis (MS) is a chronic autoimmune
disease that can affect all parts of the central
nervous system. Most patients experience
periods of neurological relapses and remissions
early in their disease course, followed by
progressive neurological deterioration [1].
There are no curative treatments for MS, but
disease-modifying therapies (DMTs) such as
interferon beta-1b are considered effective
therapies for the management of MS [2].
Long-term management with DMTs can alter
the pathological immune responses associated
with MS, prevent relapses, and reduce the risk of
disease progression [3]. Optimal management of
MS with DMTs depends on a number of factors,
including starting the treatment early and
adherence to the medication regimen [2, 4].
Nevertheless, poor adherence to DMTs is
frequently seen among patients with MS [4]
and can lead to increased risk of relapse and
higher medical costs [5, 6].
Several DMTs are given as
patient-administered injections via the use of
an autoinjector, as these devices can reduce
patients’ anxiety about self-administered
injections and contribute to a lower rate of
injection site reactions [7–9]. Moreover,
autoinjector use may be associated with
improved adherence to injectable therapy [10].
Innovations in autoinjector design have
advanced the management of MS using
injectable DMTs. For example, electronic
autoinjectors can improve the overall injection
experience by employing new technology.
Some of the new features of electronic
autoinjectors include silent injections owing
to a motorized injection process, hidden
needles, individual injection settings (e.g.,
adjustable injection speed and depth), skin
sensors to detect that the device is positioned
correctly before injection, recording of dose
history, and injection reminder functions
[4, 7, 11].
The new fully electronic BETACONNECTTM
autoinjector (Bayer Pharma AG) tested in the
current survey was developed to provide
subcutaneous interferon beta-1b therapy
(Betaseron; Bayer Pharma AG) while
incorporating innovative features to optimize
patients’ injection experience. These include
advances in autoinjector design and technology
as outlined in the following section, which may
enhance overall patient comfort and
satisfaction, improving the management of
MS. It is clear that patients’ perceptions and
preferences are vitally important, as when taken
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into account they can increase treatment
effectiveness and reduce healthcare costs [12].
The objective of the current survey was to
use a comprehensive survey-based approach to
assess patient perceptions of BETACONNECT in
comparison with their experiences using
mechanical autoinjectors that are available in
the US. This survey builds upon results from
recently published surveys which have shown
high levels of satisfaction with BETACONNECT
and preference over previous methods for
injecting interferon beta-1b therapy [13, 14].
The current survey is the first to compare
BETACONNECT with mechanical autoinjectors.
METHODS
Autoinjectors
Figure 1 shows the BETACONNECT
autoinjector. Note that the Rebismart
autoinjector (Merck Serono) was not included
as it has not been approved for use in the US,
and we also excluded those using the Rebidose
‘pen’ device (EMD Serono Inc.) as this is not an
autoinjector. Patients using injectable DMTs
such as interferon beta-1a, whether as
Avonex (Biogen) or Plegridy (Biogen)
formulations, were also excluded from this
survey as they too use pen devices rather than
autoinjectors.
A BETACONNECT device was demonstrated
to and used by survey participants to perform a
simulated injection as part of this market
research. Its main features include an intuitive
user interface and an ergonomic design making
it potentially easier to handle and allowing
one-handed injections. It has
adjustable injection speed and depth to allow
customized injection settings, and a low-force
safety release to ensure the device is positioned
correctly at the time of the injection. The nearly
silent electronic injection features four-phase
injection technology: (1) automatic needle
insertion, (2) delivery of the medication, (3)
dwell time, when the needle remains in the skin
momentarily, and, (4) automatic needle
retraction. The autoinjector provides visual
and audible signals that the injection has
finished. It also features a dose reminder
function and audible and visual indicators of
battery status. Finally, the device automatically
records data such as injection date and time,
injection depth, injection speed, and injection
volume. In due course, BETACONNECT will
offer the possibility to share data with
healthcare providers via an app called
myBETAapp and the Navigator, a dashboard
monitoring application, to enhance
communication between patients and
healthcare professionals (myBETAapp and
Navigator are currently under FDA review).
Participants
Recruitment of patients for this survey was
organized through an independent external
Fig. 1 The BETACONNECT autoinjector. Comparator
autoinjectors images and details are available from the
following websites: Copaxone Autoject/Autoject 2 [23],
Extavia Auto-injector/Auto-injector II [24], Rebif Rebi-
ject/Rebiject II [25]. Note: the RebiSmart autoinjector was
not included as it has not been approved for use in the US.
Pen injector devices such as the Rebif Rebidose were also
excluded as they are not autoinjectors
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market research company that conducted
screening telephone calls to select patients
with MS from their database of participants
who had previously expressed a willingness to
participate in market research projects. Patients
were included if they lived in the US, were aged
18–70 years, had a relapsing form of MS, and
sometimes or always used an autoinjector to
self-administer either glatiramer acetate/
Copaxone (Teva Pharmaceuticals USA, Inc.;
Copaxone Autoject or Autoject 2), interferon
beta-1b/Extavia (Novartis Pharmaceuticals
Corp.; Extavia Auto-Injector or Auto-Injector
II), or interferon beta-1a/Rebif (EMD Serono
Inc.; Rebif Rebiject or Rebiject II). Exclusion
criteria were a diagnosis less than 6 months ago
or a diagnosis of primary progressive MS
(PPMS).
Survey Instruments and Data Collection
Data were collected from patients with MS
between August and September 2015 through
in-person 60-min structured interviews in 12
cities throughout the US: Philadelphia, New
York City, Atlanta, Miami, Tampa, Chicago, Las
Vegas, Phoenix,Houston, Dallas, Los Angeles and
Seattle. Signed informed consent to participate
was obtained from all participants, who also had
to bring their current autoinjector with them.
The interview consisted of four stages. Stage
1: introduction and background. In this stage
patients gave information on their MS
diagnosis, and their MS disease and treatment
history. Stage 2: unmet needs and satisfaction
with current autoinjector. In this stage patients
were presented with a list of 18 possible
autoinjector attributes (Table S1 in the
supplementary material) and asked to indicate
how important each attribute would be in an
ideal autoinjector, rating them from 1 (not
important) to 10 (most important) and
instructed to only assign the maximum rating
of 10 to one attribute. Patients indicated how
well their own autoinjectors performed across
the same 18 attributes, rating from 1 (not well at
all) to 10 (very well). Stage 3: BETACONNECT
demonstration and ‘‘simulated injection’’. Here,
the interviewer showed the patients a
BETACONNECT autoinjector with all branding
and identifiers masked. For the purposes of this
research, the BETACONNECT autoinjector
contained an empty syringe, but no needle.
The patients were first shown how to use
BETACONNECT and then how to perform a
‘‘simulated injection’’. The patients next used
BETACONNECT, first being guided through the
device features and the injection process and
then performing simulated self-injections at
various injection sites. Stage 4:
BETACONNECT assessment. Here, patients
were again presented with the list of 18
autoinjector attributes (Table S1) and asked to
rate how well the BETACONNECT autoinjector
performed across these attributes, rating from 1
(not well at all) to 10 (very well). Patients
compared their current autoinjector with
BETACONNECT, agreeing or disagreeing with
a number of statements by assigning a rating
from 1 (strongly disagree) to 10 (strongly agree;
Table S2 in the supplementary material).
Finally, patients answered general queries
about their choices, including which features
they liked the most and the least, and why, and
whether they would prefer using
BETACONNECT or their autoinjector.
Specifically, patients were asked ‘‘Assuming
your current MS medication can use the new
autoinjector, please select the one statement
that best describes your overall preference: (1) I
would rather use the new autoinjector than my
current autoinjector or (2) I would rather
continue to use my current autoinjector than
this new autoinjector.’’
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The survey was funded by Bayer HealthCare
Pharmaceuticals, Inc., Whippany, New Jersey,
USA. Patients were compensated for their time
and travel costs to the market research facilities.
All procedures followed were in accordance
with the 1964 Declaration of Helsinki and its
subsequent revisions. This article describes a
non-interventional survey, and so does not
involve any new studies of human or animal
subjects performed by any of the authors.
RESULTS
Demographic Characteristics
A total of 90 respondents with MS agreed to
participate, and completed the survey (Table 1).
Of these, 63 (70%) were using autoinjectors for
Copaxone, 25 (28%) for Rebif, and 2 (2%) for
Extavia. This distribution of patients is
somewhat representative of these products’
current sales market share for injectable DMTs
within the US. Because of the small number of
patients taking Extavia, no individual
comparisons were made for this group with
BETACONNECT but the results for the Extavia
group were included in overall (all patient)
comparisons. Approximately three-quarters
(78%) of respondents were female.
Ideal Autoinjector Attributes
Figure 2 shows the most important features of
an ideal autoinjector according to the
percentage of patients who assigned a high
score of 8, 9, or 10 (top three scores on a
10-point scale) for each attribute. The most
highly valued attributes were: the injection
process is easy overall (96%), easy to push the
button to start the injection (88%), and
autoinjector is comfortable to hold during
injections (86%). Other features that were
rated highly included the ability to use the
autoinjector without help from others (83%),
adjustable injection depth (81%), and being
able to reach different injection sites (78%).
Patients were also asked to assign the
maximum rating of 10 to only one of the
attributes. The ideal autoinjector attribute
given the most number of maximum scores
was the injection process is easy overall (26%),
with the ability to use the autoinjector
without help from others and the sound of
injection is minimal (quiet) both gaining the
next highest number of maximum scores
(11% each).
Comparison of Current Autoinjector With
BETACONNECT
Patients rated their own autoinjector using the
same ideal autoinjector attributes mentioned
previously, and results for individual
autoinjectors are displayed in Fig. 3. This
figure also shows the results of patients rating
BETACONNECT across the same attributes
following a demonstration and simulated
self-injections with BETACONNECT. Moreover,
this figure shows that BETACONNECT
outperforms the Copaxone Autoject or
Autoject 2 and Rebif Rebiject or Rebiject II
across all the attributes. Figure 4 shows the
percentage of patients who assigned a high
score of 8, 9, or 10 on a 10-point scale to
statements concerning their attitudes and
perceptions towards BETACONNECT in
comparison with their current autoinjector.
Built-in dwell time (i.e., the time the needle
remains in the skin after the medication has
been injected) was most valued (97%), followed
by the self-check feature (84%), greater ability to
customize injections (84%) and adjustment of
injection speed (83%). The subsequent
assessment of overall autoinjector preference
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revealed that 83% of patients preferred
BETACONNECT to their current autoinjector,
as they agreed with the statement ‘‘I would
rather use the new autoinjector than my current
autoinjector’’ (Fig. 5). The main reasons for the
preference for BETACONNECT were ease of
injection, user-friendly functions such as
built-in dwell time and automatic needle
retraction, and quiet injections. Preference was
also analyzed by patient age group (Table 2),
showing a high (100%) preference for
BETACONNECT in younger patients (i.e.,
18–40 years of age), with older patients slightly
less likely to switch.










Northeast (Philadelphia, New York City) 16 (18%)
Southeast (Atlanta, Miami, Tampa) 22 (24%)
Midwest (Chicago) 7 (8%)
Southwest (Las Vegas, Phoenix, Houston, Dallas) 27 (30%)
West (Los Angeles, Seattle) 18 (20%)
Current MS medicationa and autoinjectorb
Copaxone (Copaxone Autoject/Copaxone Autoject 2) 63 (70%)
Rebif (Rebif Rebiject/Rebif Rebiject II) 25 (28%)
Extavia (Extavia Auto-injector/Extavia Auto-injector II) 2 (2%)
MS type
Relapsing–remitting MS (RRMS) 87 (97%)
Secondary progressive MS (SPMS) 3 (3%)c
Clinically isolated syndrome (CIS) 1 (1%)
Progressive–relapsing MS (PRMS) 0 (0%)
MS Multiple sclerosis
a The distribution of patients taking these medications is somewhat representative of these drugs market share within the
US, hence the small proportion taking Extavia
b It was not possible for this study to include the RebiSmart autoinjector as it is not licensed in the US where this survey
took place. Pen injector devices such as the Rebif Rebidose were also excluded as they are not autoinjectors
c Includes one patient with a diagnosis of secondary progressive MS and relapsing–remitting MS
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DISCUSSION
The first part of this survey investigated what
patients thought might be ideal autoinjector
attributes. The most important features focused
on being easy to use, comfortable to hold,
customization for optimal comfort during
injections, and being able to self-inject
without help and so maintain independence.
These results are in broad agreement with
previous published results. For example, a
survey of patients with MS showed that the
main reason for not self-injecting was physical
difficulty in performing the injections (57%)
[15]. Another survey showed that major
concerns preventing self-injection were fear of
performing injections properly and ability to
access various injection sites (both 47%) [16]. A
decline in fine motor skills is a common
problem among patients with MS, reducing
their ability to administer injections [4]. Thus,
improvements in autoinjector ease of use are
vital to allow patients to fulfill their desire to
maintain their independence by performing
self-injections.
It is interesting to note that while some of
the features of BETACONNECT were not
thought to be of major importance among the
ideal autoinjector attributes (e.g.,
adjustable injection speed), they were rated
more highly once patients had performed
simulated injections with BETACONNECT.
This may be because patients were not aware
what features were potentially feasible as they
Push start button easily 
77%
Reminder function 
Adjustable injection speed 
Know when to remove needle 
Injection process easy overall 
Minimal steps to prepare autoinjector 
Intuitive to use 
Prevents accidental injections 
Audible cues 
Comfortable to hold 
Adjustable injection depth 
Easy pressure application to start 












Can reach different sites 
Quiet injection 
Modern look and feel 









Fig. 2 Ideal autoinjector attributes rating from 1 to 10 (where 10 is most important and 1 least important). The
percentages represent the proportion of patients who selected a rating of 8, 9 or 10 for each attribute
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had not encountered them at this stage of the
survey. Another example of this phenomenon
was quietness of injection, which was overall
rated rather low among the initial assessment of
ideal autoinjector attributes as assessed by the
percentage giving a score of 8, 9, or 10, even
though it was the second most desirable
attribute according to the number of
maximum scores. The results reveal an
interesting dichotomy: prior to encountering
BETACONNECT patients thought quiet
injections were either not an important
attribute or regarded it as major issue. After
patients had experienced quiet simulated
injections using BETACONNECT many
changed their opinions, as 63% of patients
thought that lack of a loud noise upon
injection would reduce their anxiety (Fig. 4).
While BETACONNECT outperformed
Copaxone Autoject or Autoject 2 and Rebif
Rebiject or Rebiject II over all of the
autoinjector attributes, this outperformance
was particularly marked in features that were
not highly rated in the initial assessment of
Fig. 3 BETACONNECT, Autoject and Rebiject, com-
pared individually against an ideal autoinjector across 18
attributes. Attribute ratings for an ideal autoinjector are
also shown (green bars). Autoject, Rebiject and BETA-
CONNECT were rated based on how well they performed
across the attributes, from 1 (not well) to 10 (very well).
For each attribute, the percentage of patients who selected
a rating of 8, 9, or 10 for each autoinjector using symbols as
shown in the legend. Note: we did not compare Extavia
patients separately vs. other groups because there were only
two patients using Extavia. The other groups had enough
patients for us to analyze and compare them. The two
patients using Extavia autoinjectors were included in the
total number of 90 patients (all patients following the
demonstration and simulated injections with
BETACONNECT)
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attributes prior to performing simulated
injections with the new autoinjector (e.g.,
injection reminders, audible cues, quietness of
injection, ability to adjust injection speed, and
knowing when to remove the needle). This
strongly suggests that the improvements in
autoinjector design featured in
BETACONNECT may be meeting the patients’
needs, even needs that they were unaware of
before using it. It is worth noting here that we
were unable to include the RebiSmart
autoinjector in the survey as it has not been
approved for use in the US.
The main reasons for the preference for
BETACONNECT in the current survey appear
to be the ease of injection (e.g., minimal
pressure needed to press the injection button,
helping patients to reach various injection sites
across the body); user-friendly features such as
built-in dwell time and automatic needle
retraction; visible/audible cues denoting when
the injection is complete to prevent premature
needle withdrawal; and the quiet nature of the
injection. Likewise, the minority who preferred
to use their current autoinjector tended to be
older, more concerned about potential
Requires less assistance 40%
Increases independence 43%
Will be able to use more injection sites 51%
May improve adherence to medication 58%
Quiet injections will reduce anxiety 63%
More comfortable to handle 63%
Better look and feel 67%
79%
69%
Customizing speed/depth may reduce pain 69%
Reminder reduces chance of forgetting injections 71%
More comfortable injections 74%
Injection process is easier 78%
Lights/button make operation self-explanatory 
83%Injection sound is more user-friendly 
83%Automatic needle retraction is valuable 
Adjusting injection speed may increase comfort 83%
Greater ability to customize injections 84%
Self-check feature will improve reliability 84%
Built-in dwell time ensures full drug delivery 97%
Less anxiety with new autoinjector 
n = 90
Fig. 4 Attitudes and perceptions towards BETACON-
NECT in comparison with patients’ current autoinjectors,
showing the percentage who scored statements 8, 9, or 10
(where 1 is strongly disagree and 10 is strongly agree). The
percentages represent the proportion of patients who
selected a rating of 8, 9, or 10 for each statement
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electronic malfunctions, preferred their ‘less
bulky’ current device, or were just used to
their current autoinjector and unwilling to
change.
The BETACONNECT attributes valued by
most patients were knowing when to pull the
needle out after an injection (99%),
adjustable injection speed (99%), visual cues to
show injection progress (98%), being able to use
without help (98%), easy to push a button to
start injections (97%), and being easy to tell
when an injection starts and stops (97%; Fig. 3).
In addition, the new autoinjector features
valued by patients over their current auto
injector were the built-in dwell time (97%),
self-check function (84%), injection speed
adjustment (83%), low injection noise (83%),
and automatic needle retraction (83%; Fig. 4).
Considering these results together, they reflect
the key features of BETACONNECT that make it
particularly useful for patients with MS, notably
automatic needle insertion and retraction,
audio/visual cues that indicate the injection
progress and the successful end of an injection,
and adjustable injection speed and depth to
allow customized injection settings. Automatic
needle insertion, dwell time, and retraction, in
conjunction with visual and audible signals,
ensure that injections are delivered completely.
This meets common concerns that the injection
might not be performed correctly [16]; many
patients in the current survey said they counted
to ten when using their mechanical
Fig. 5 Patient overall autoinjector preference and main underlying reasons
Table 2 Preference for BETACONNECT by age group







a Number of patients in each age group who would rather
use BETACONNECT than their current autoinjector
b Total number of patients in each age group
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autoinjector to avoid spilling medication.
Moreover, the customized settings of
BETACONNECT may help overcome a major
barrier to DMT adherence for patients with MS,
as one survey showed that 34% of patients did
not use their injection device as they wanted to
control their injections, including control of
the speed and depth of needle insertion [16].
BETACONNECT also features a unique injection
reminder function. While only 71% of patients
thought that the reminder function might be
helpful (Fig. 4), this feature may become more
important with use, as forgetting to take
medications for MS is the most common
reason for non-adherence to MS drug therapy,
owing to the cognitive changes that form part
of the natural disease course [17, 18].
Strengths of the survey included the in-depth
nature of each interview, lasting about an hour
for each patient, as well as the time spent by
patients handling and performing simulated
injections with BETACONNECT. Potential
weaknesses of the current survey are that it was
performed in an uncontrolled setting and
without a longitudinal follow-up, and that it
had a relatively small sample size. Paying
patients’ expenses to participate in the survey
might bias them towards BETACONNECT, but
patients were also blinded to any name or
branding on the BETACONNECT to help reduce
suchprejudice.Anotherpotential criticismof the
current survey is the relative distribution of
autoinjector types, with 70% using
autoinjectors for Copaxone, 28% for Rebif, and
only 2% for Extavia. However, this distribution
reflects the generally higher prevalence of
Copaxone and Rebif patients in the US and the
difficulty in recruiting patients taking Extavia,
given the low level of Extavia use. In addition,
from January to December 2015, only 29% of
total Rebif prescriptions were for Rebif Rebidose
and 71% were for Rebif that could be injected
with a mechanical autoinjector [19]. Betaseron
patients were excluded as patient satisfaction
surveys with patients using BETACONNECT
were conducted previously [13, 14]. The current
survey does not contain adherence data, so we
cannot know for sure that BETACONNECT will
increase adherence to DMTs. Clearly, adherence
to DMTs is of great importance as it may reduce
the incidence of relapses, lead to fewer
hospitalizations and avoid excess use of
healthcare resources [4]. Other studies have
shown promising adherence rates with other
electronic autoinjectors usedbypatientswithMS
[20, 21]. Several BETACONNECT studies to
investigate adherence are on-going or are
planned to start shortly to investigate this issue.
CONCLUSIONS
Adherence to DMTs is vital to optimize
treatment efficacy and so improve patient
outcomes, but it nevertheless remains a
challenge [4, 22]. Ongoing improvements in
autoinjector design and functionality as
exemplified by BETACONNECT may allow
patients with MS to overcome many
self-injection difficulties that can, for example,
result in poor adherence to MS drug therapy. In
the current survey, BETACONNECT attributes
and features were rated highly by patients,
compared with both an ideal autoinjector and
their current mechanical autoinjector. As such,
these findings suggest that the use of
BETACONNECT may increase patient
satisfaction and potentially increase overall
medication adherence.
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